Combination therapy improves progression-free survival for patients with metastatic dMMR colorectal cancer

Patients with deficient DNA mismatch repair (dMMR) oregon microsatellite instability-high (MSI-H) metastatic colorectal crab experienced a 58% simplification successful the hazard of illness progression oregon decease erstwhile treated with atezolizumab (Tecentriq) positive modified FOLFOX6 and bevacizumab (Avastin), compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT proceedings published successful the Journal of Clinical Oncology. The operation besides produced higher effect rates and substantially reduced superior illness progression.